RARE
Price:
$47.24
Market Cap:
$4.36B
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hyper...[Read more]
Industry
Biotechnology
IPO Date
2014-01-31
Stock Exchange
NASDAQ
Ticker
RARE
According to Ultragenyx Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.24B. This represents a change of -3.99% compared to the average of 4.42B of the last 4 quarters.
The mean historical Enterprise Value of Ultragenyx Pharmaceutical Inc. over the last ten years is 3.35B. The current 4.24B Enterprise Value has changed 12.55% with respect to the historical average. Over the past ten years (40 quarters), RARE's Enterprise Value was at its highest in in the December 2020 quarter at 8.29B. The Enterprise Value was at its lowest in in the December 2014 quarter at 1.38B.
Average
3.35B
Median
2.88B
Minimum
1.24B
Maximum
7.76B
Discovering the peaks and valleys of Ultragenyx Pharmaceutical Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 284.07%
Maximum Annual Enterprise Value = 7.76B
Minimum Annual Increase = -42.27%
Minimum Annual Enterprise Value = 1.24B
Year | Enterprise Value | Change |
---|---|---|
2023 | 3.35B | 6.65% |
2022 | 3.14B | -42.27% |
2021 | 5.44B | -29.94% |
2020 | 7.76B | 284.07% |
2019 | 2.02B | -1.51% |
2018 | 2.05B | 9.76% |
2017 | 1.87B | -28.74% |
2016 | 2.62B | -34.98% |
2015 | 4.03B | 225.88% |
2014 | 1.24B | 1.40% |
The current Enterprise Value of Ultragenyx Pharmaceutical Inc. (RARE) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
3.97B
5-year avg
4.34B
10-year avg
3.35B
Ultragenyx Pharmaceutical Inc.’s Enterprise Value is greater than X4 Pharmaceuticals, Inc. (38.44M), greater than Terns Pharmaceuticals, Inc. (222.97M), greater than Day One Biopharmaceuticals, Inc. (963.46M), greater than PDS Biotechnology Corporation (53.10M), greater than Inozyme Pharma, Inc. (202.73M), greater than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (291.98M), greater than Apellis Pharmaceuticals, Inc. (3.90B), less than Crinetics Pharmaceuticals, Inc. (4.93B), greater than Arvinas, Inc. (1.69B), less than Revolution Medicines, Inc. (9.43B), greater than Kura Oncology, Inc. (807.00M), greater than Acumen Pharmaceuticals, Inc. (139.19M), less than Incyte Corporation (12.55B), less than Alnylam Pharmaceuticals, Inc. (31.79B), less than United Therapeutics Corporation (15.49B),
Company | Enterprise Value | Market cap |
---|---|---|
38.44M | $57.64M | |
222.97M | $491.80M | |
963.46M | $1.38B | |
53.10M | $78.19M | |
202.73M | $180.51M | |
3.91B | $4.12B | |
291.98M | $361.25M | |
3.90B | $3.83B | |
4.93B | $5.20B | |
1.69B | $1.78B | |
9.43B | $9.55B | |
807.00M | $839.85M | |
139.19M | $142.39M | |
12.55B | $13.82B | |
31.79B | $31.59B | |
15.49B | $16.65B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ultragenyx Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ultragenyx Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Ultragenyx Pharmaceutical Inc.'s Enterprise Value?
What is the highest Enterprise Value for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the 3-year average Enterprise Value for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the 5-year average Enterprise Value for Ultragenyx Pharmaceutical Inc. (RARE)?
How does the current Enterprise Value for Ultragenyx Pharmaceutical Inc. (RARE) compare to its historical average?